Moderna, Inc. $MRNA Stock Acquired by Bessemer Group Inc.

Bessemer Group Inc. boosted its stake in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 88.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,006 shares of the company’s stock after purchasing an additional 4,701 shares during the quarter. Bessemer Group Inc.’s holdings in Moderna were worth $1,927,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Dogwood Wealth Management LLC boosted its holdings in shares of Moderna by 158.8% in the 3rd quarter. Dogwood Wealth Management LLC now owns 132 shares of the company’s stock valued at $25,000 after purchasing an additional 81 shares during the last quarter. Western Pacific Wealth Management LP acquired a new stake in shares of Moderna during the 3rd quarter worth $29,000. CENTRAL TRUST Co increased its holdings in shares of Moderna by 36.5% during the 3rd quarter. CENTRAL TRUST Co now owns 172 shares of the company’s stock worth $33,000 after buying an additional 46 shares during the last quarter. Next Level Wealth Planning LLC acquired a new stake in shares of Moderna during the 3rd quarter worth $34,000. Finally, Ramsey Quantitative Systems purchased a new position in shares of Moderna in the 3rd quarter worth $40,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Trading Down 2.6%

MRNA opened at $194.18 on Friday. The firm has a market capitalization of $78.57 billion, a P/E ratio of -27.35 and a beta of 1.16. The firm’s 50 day moving average is $207.87 and its 200-day moving average is $100.37. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $280.80. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($1.10) by $1.48. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The business’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.51) earnings per share. Analysts expect that Moderna, Inc. will post -5.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other Moderna news, President Stephen Hoge sold 40,294 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the completion of the transaction, the president directly owned 1,525,858 shares of the company’s stock, valued at $219,921,913.54. This represents a 2.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Jamey Mock sold 34,836 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the transaction, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 275,626 shares of company stock worth $50,776,076 in the last quarter. 10.80% of the stock is owned by corporate insiders.

Key Headlines Impacting Moderna

Investors following MRNA have been watching these headlines:

  • Positive Sentiment: Moderna’s personalized melanoma vaccine, used with Merck’s Keytruda, reduced the risk of recurrence or death in a Phase 3 trial. The results support the potential of its oncology pipeline, although positive trial news has not prevented the recent pullback. Article: Moderna's Cancer Vaccine Worked
  • Negative Sentiment: Investors are concerned that Moderna’s 2027 cash costs could reach $4 billion. The spending burden, alongside uncertain revenue from its expanding vaccine and oncology pipeline, raises questions about funding its next phase of growth. Article: Moderna's 2027 Cash Costs
  • Neutral Sentiment: Bireme Capital disclosed that it sold its Moderna position after the stock’s rally. That reflects one manager’s portfolio decision, rather than a company announcement. Article: Bireme Capital Sold Moderna

Analysts Set New Price Targets

MRNA has been the subject of a number of research reports. Royal Bank Of Canada reissued a “sector perform” rating and set a $130.00 price target on shares of Moderna in a research report on Wednesday, August 19th. Piper Sandler reaffirmed an “overweight” rating and issued a $305.00 price objective (up from $230.00) on shares of Moderna in a research note on Monday, November 9th. Argus raised Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research note on Friday, August 28th. Bradesco Corretora upgraded Moderna to an “outperform” rating in a report on Friday, August 28th. Finally, Wolfe Research raised shares of Moderna from an “underperform” rating to a “peer perform” rating in a research report on Tuesday, August 25th. Six analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $120.25.

Read Our Latest Stock Analysis on MRNA

Moderna Profile

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Further Reading

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.